FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * TOTH A ERNEST JR 2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [ AQST ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP, Chief Financial Officer
(Last)         (First)         (Middle)
C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)
6/15/2021
(Street)
WARREN, NJ 07059
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Purchase)  $4.04  6/15/2021    A     120000       (1) 6/15/2031  Common Stock  120000  $0  120000  D   

Explanation of Responses:
(1)  Grant to the Reporting Person of a stock option to purchase Common Stock of the Issuer under the Issuer's 2018 Equity Incentive Plan (the "Plan"). Said options vest over a three-year period, with 25% of such option vesting on each of the one-year and two-year anniversaries of the option vesting commencement date and the remaining 50% vesting on the third-year anniversary of the option vesting commencement date, provided that at the relevant vesting date, the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan. The option expires ten years after the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
TOTH A ERNEST JR
C/O AQUESTIVE THERAPEUTICS, INC.
30 TECHNOLOGY DRIVE
WARREN, NJ 07059


SVP, Chief Financial Officer

Signatures
/s/ Lori J. Braender, as Attorney-In-Fact 6/17/2021
**Signature of Reporting Person Date
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Aquestive Therapeutics Charts.
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Aquestive Therapeutics Charts.